Allen Tamara L, Matthews Vance B, Febbraio Mark A
Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, 6492, St Kilda Road Central, Melbourne, 8008, VIC, Australia.
Handb Exp Pharmacol. 2011(203):179-99. doi: 10.1007/978-3-642-17214-4_9.
The incidence of obesity and related co-morbidities such as insulin resistance, dyslipidemia and hypertension are increasing at an alarming rate worldwide. Current interventions seem ineffective to halt this progression. With the failure of leptin as an anti-obesity therapeutic, ciliary neurotrophic factor (CNTF) has proven efficacious in models of obesity and leptin resistance, where leptin proved ineffective. CNTF is a gp130 ligand that has been found to act centrally and peripherally to promote weight loss and insulin sensitivity in both human and rodent models. Future research into novel gp130 ligands may offer new candidates for obesity-related drug therapy.
肥胖症以及诸如胰岛素抵抗、血脂异常和高血压等相关合并症在全球范围内正以惊人的速度增长。目前的干预措施似乎无法有效阻止这一进程。随着瘦素作为一种抗肥胖疗法的失败，睫状神经营养因子（CNTF）已在肥胖症和瘦素抵抗模型中被证明是有效的，而在这些模型中瘦素被证明无效。CNTF是一种gp130配体，已发现在人和啮齿动物模型中，它在中枢和外周发挥作用以促进体重减轻和胰岛素敏感性。对新型gp130配体的未来研究可能会为肥胖相关药物治疗提供新的候选药物。
